Abstract:
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin, more commonly the "JUPITER trial," recently concluded daily administration of the drug rosuvastatin, known commercially as Crestor, reduces the risk of a future heart attack by up to 60 percent in otherwise perfectly healthy individuals.
The study, sponsored by the drug's manufacturer AstraZeneca, has been hailed as groundbreaking by some and portentous by others-are we actually taking the first steps toward a society similar to those depicted in White Noise, 1984 and Fahrenheit 451? Both sides of a divided Royal Purple staff weigh in....
Mgood
posted 11/19/08 @ 7:41 AM CST